Modulating microglia activity with PPAR-γ agonists: a promising therapy for Parkinson's disease?
about
Fundamental role of pan-inflammation and oxidative-nitrosative pathways in neuropathogenesis of Alzheimer's disease in focal cerebral ischemic ratsFundamental role of pan-inflammation and oxidative-nitrosative pathways in neuropathogenesis of Alzheimer's diseasePioglitazone ameliorates the phenotype of a novel Parkinson's disease mouse model by reducing neuroinflammationThe antidepressant-like effects of pioglitazone in a chronic mild stress mouse model are associated with PPARγ-mediated alteration of microglial activation phenotypes.Influence of Estrogen Modulation on Glia Activation in a Murine Model of Parkinson's DiseaseNuclear receptors in neurodegenerative diseases.Induction of microglial toll-like receptor 4 by prothrombin kringle-2: a potential pathogenic mechanism in Parkinson's diseaseImmunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease.Lack of Genetic Associations of PPAR-γ and PGC-1α with Alzheimer's Disease and Parkinson's Disease with Dementia.Alterations in neuronal morphology and synaptophysin expression in the rat brain as a result of changes in dietary n-6: n-3 fatty acid ratiosPathogenesis-targeted, disease-modifying therapies in Parkinson disease.Molecular basis of alcoholism.The ongoing pursuit of neuroprotective therapies in Parkinson disease.Role of Microglia in Neurological Disorders and Their Potentials as a Therapeutic Target.PPARs in the central nervous system: roles in neurodegeneration and neuroinflammation.The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson's disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain.Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.
P2860
Q26747585-B9B1D87F-1B1A-4E66-8761-E0B78D407122Q26748713-122E6A98-6795-4AC1-BE51-F9A7B4578255Q27301100-0D437944-31AA-4528-B5B0-2AFDEE0A55FFQ27303048-71BC9E01-9BE3-4E12-8FE1-B963F7B32855Q33740654-7275DD95-C9DC-4E03-B9EF-543F873E42D0Q34580020-843E9059-57B9-427B-B91E-669E3537CF14Q36123393-4EDAEBA1-9D88-4796-8EC9-9216230C1929Q36474039-AC6793F3-4365-4F37-8AFE-50E530EF1250Q36896649-8C4BC17C-24AB-4EE8-A05C-1B5DC628D72BQ37071931-07094F4E-31A5-424F-B6CE-D065CA31AF89Q37506492-04BFF9AD-14D3-4E0F-97E2-133EF18E29C7Q38259368-197950FE-4505-464F-AB1B-07AC7CDD0D81Q38275171-5B9519C5-BBA7-49C4-96C3-E723B2CAF375Q39004244-853D4A41-ECB7-4623-98DE-656BDD83D091Q39145017-93306D65-CDDA-46DB-9E90-02219370072DQ41683709-1FB49A54-3B2E-45F5-82FB-5051D40581CBQ43679571-B03876CF-94CC-45EA-9D6D-075894936208
P2860
Modulating microglia activity with PPAR-γ agonists: a promising therapy for Parkinson's disease?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Modulating microglia activity ...... erapy for Parkinson's disease?
@en
type
label
Modulating microglia activity ...... erapy for Parkinson's disease?
@en
prefLabel
Modulating microglia activity ...... erapy for Parkinson's disease?
@en
P2860
P1476
Modulating microglia activity ...... erapy for Parkinson's disease?
@en
P2093
Anna R Carta
P2860
P2888
P304
P356
10.1007/S12640-012-9342-7
P577
2012-08-07T00:00:00Z
P6179
1021369310